June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 26, 2025

First Targeted Therapy Approved for BP

The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.

Conexiant

June 26, 2025

MRI Finds Hidden Arthritis After Cancer Therapy

A new imaging study found that patients who develop joint pain after cancer immunotherapy often show significant inflammation and joint damage on MRI—even when physical signs of arthritis are absent.

Conexiant

June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant

June 19, 2025

GLP-1 Use Associated with Less Pain, Fatigue

At the EULAR 2025 Congress, researchers reported that GLP-1 receptor agonists were linked to reduced opioid use, pain, and fatigue in fibromyalgia patients based on a large real-world analysis.

Conexiant

June 16, 2025

Updated Guidance on Antirheumatic Drug Use

New 2024 EULAR recommendations offer evidence-based guidance for the use of antirheumatic drugs during pregnancy, lactation, and conception planning in patients with rheumatic and musculoskeletal diseases.

Conexiant

June 10, 2025

New Tool May Identify Patients at High Risk of Developing RA

New criteria may aid in identifying patients with joint pain who are at high risk of developing rheumatoid arthritis, enabling earlier intervention and better trial recruitment.

Conexiant

June 02, 2025

Glycosylated IgG Disrupts Kidney Cell Metabolism: Study 

Children with lupus nephritis had altered IgG sugar chains that impaired kidney cell metabolism, and removing those sugars reversed the injury in lab tests.

Conexiant

June 02, 2025

Only 20% Account for 80% of Steroid Use: Study

In a UK-wide analysis of nearly 2 million patients, researchers found that “a fifth of patients receiving corticosteroids accounted for over 80% of oral and inhaled corticosteroid prescribing,” highlighting concentrated use and variable treatment persistence across formulations.

Conexiant